DFTX Overview

Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Wall Street analysts forecast DFTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DFTX is35.89 USD with a low forecast of 20.00 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Definium Therapeutics Inc revenue for the last quarter amounts to -59.22M USD, increased 84.15

Definium Therapeutics Inc. EPS for the last quarter amounts to -42631000.00 USD, increased 44.91

Definium Therapeutics Inc (DFTX) has 105 emplpoyees as of May 11 2026.

Today DFTX has the market capitalization of 2.40B USD.